Last updated: February 24, 2026
What is the drug associated with NDC 51407-0656?
NDC 51407-0656 corresponds to Doxorubicin Hydrochloride Injection, USP. It is a chemotherapy agent used primarily in the treatment of various cancers, including breast cancer, bladder cancer, and others. It is administered intravenously and is part of anthracycline class drugs.
Market Size and Demand Dynamics
Global Cancer Treatment Market
The global oncology drug market was valued at approximately USD 165 billion in 2021, with plans for growth to USD 250 billion by 2027, registering a CAGR of approximately 7%. Doxorubicin remains a standard chemotherapeutic agent, used across multiple cancer types.
Doxorubicin Specific Market
- Remains a backbone agent in chemotherapy regimens.
- Market penetration is high in developed nations; usage in emerging markets is expanding.
- Estimated global consumption: approx. 15 metric tons annually (2021 estimate), primarily driven by the US, Europe, and emerging markets like China and India.
Competitive Landscape
- Several generic manufacturers produce doxorubicin, leading to fierce price competition.
- Brand-name versions (e.g., Pfizer's Adriamycin) retain market presence, often at premium pricing.
- Biosimilars or new formulations are under development but have limited commercial impact so far.
Regulatory and Patent Status
- The patent for original formulations expired in the early 2000s.
- Multiple generic approvals are active globally.
- No recent patent litigations or exclusivity extensions reported.
Price Analysis
Current Pricing Trends (as of 2023)
| Formulation |
Price per vial (USD) |
Typical dose |
Cost per treatment cycle |
| 50 mg vial (generic) |
$80–$120 |
50 mg dose |
$160–$240 |
| 15 mg vial (brand, avg.) |
$50–$70 |
15 mg dose |
$150–$210 |
- Generic formulations: dominate due to lower prices.
- Brand-name formulations: priced 30-50% higher than generics.
Price Projections
- Short-term (1–2 years): prices expected to remain stable due to generic competition and existing supply agreements.
- Mid-term (3–5 years): potential slight decline (~5–10%) driven by market saturation and new biosimilar entrants.
- Long-term (5+ years): possible stabilization or reduction if newer, targeted therapies replace traditional chemotherapy.
Factors Influencing Price Trends
- Increased use of biosimilars could drive prices downward.
- Supply chain disruptions could cause price spikes temporarily.
- Healthcare policy changes aiming to reduce drug costs could impact pricing strategies.
Market Drivers and Constraints
Drivers
- Rising cancer incidence globally.
- Expansion in healthcare infrastructure and cancer screening.
- Adoption of combination chemotherapies including doxorubicin.
Constraints
- Toxicity profile of doxorubicin, such as cardiotoxicity, limits usage in some patients.
- Emergence of targeted therapies may replace traditional chemotherapeutics over time.
Key Takeaways
- The doxorubicin market remains significant, driven by widespread cancer treatment protocols.
- Generic versions dominate, keeping prices relatively low and stable.
- Price declines are expected gradually due to biosimilar competition.
- Market growth will depend on cancer prevalence, treatment guidelines, and alternative therapies emerging.
- Pricing policies and healthcare reforms may influence future costs, especially in public healthcare systems.
FAQs
1. Who are the primary competitors for NDC 51407-0656?
Multiple generic manufacturers produce doxorubicin, including Hikma Pharmaceuticals, Sun Pharmaceutical, and Pfizer, which also holds the brand-name product Adriamycin.
2. What factors could significantly alter pricing trends?
Introduction of biosimilars, patent litigations, regulatory changes, and shifts in treatment standards toward targeted therapies.
3. How does the toxicity of doxorubicin impact its market?
Cardiotoxicity limits use in some patient populations, potentially influencing demand and encouraging research into less toxic alternatives.
4. Are there emerging formulations or delivery methods for doxorubicin?
Yes. Liposomal formulations (e.g., Doxil) extend the drug's half-life and reduce toxicity but are pricier and constitute a smaller market segment.
5. How does geographic variation influence pricing?
Pricing varies by country due to regulatory environments, healthcare policies, and market competition, with higher prices often in countries with lower generic penetration.
References
[1] IQVIA Institute. (2023). The Global Oncology Market Report.
[2] Medpace. (2022). Chemotherapy drugs market analysis.
[3] CDC. (2021). Cancer Treatment and Prevention Statistics.
[4] FDA. (2022). List of approved biosimilars and generic drugs.
[5] EvaluatePharma. (2022). Oncology market forecast 2022–2027.
